04
Oct-2017
Oct-2017
FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A
TORONTO, ON (September 25, 2017) – Ontario oncology innovations investor FACIT congratulates Fusion Pharmaceuticals (“Fusion”), a developer of novel targeted alpha particle radiotherapies, on completing a second closing of its oversubscribed Series A financing. This brings the total capital raised in this round to US$46 million. FACIT participated in both, this latest closing and as an early seed investor in Fusion, and is pleased to continue to support the company.
For full release from OICR News, please click here